Fredun Pharmaceuticals Limited has filed mandatory insider trading disclosure documents with BSE Limited following the recent conversion of 1,06,668 warrants into equity shares by promoter Fredun Nariman Medhora. The disclosure, submitted on March 26, 2026, complies with Regulation 7(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015.

Warrant Conversion and Share Allotment Details

The Board of Directors meeting held on March 25, 2026, from 05:00 p.m. to 05:35 p.m., approved the conversion of warrants after receiving the requisite balance consideration of Rs. 10,00,01,250. Mr. Fredun Nariman Medhora, Managing Director and promoter, exercised his conversion rights for 1,06,668 warrants into equivalent equity shares.

Shareholding Pattern Changes

According to the SEBI Form C disclosure, the warrant conversion has resulted in significant changes to the promoter's shareholding pattern. Prior to the conversion, Fredun Nariman Medhora held 1,79,672 equity shares representing 3.35% of the company's shareholding.

Regulatory Compliance and Documentation

The company has fulfilled all disclosure requirements under SEBI (Prohibition of Insider Trading) Regulations, 2015, with Company Secretary and Compliance Officer Vaishnavi Sahu submitting the necessary documentation to BSE Limited. The conversion follows the preferential issue framework established under Chapter V of the SEBI ICDR Regulations 2018.

The newly allotted equity shares have been issued in dematerialized form and rank pari passu with existing equity shares in all respects. The warrant allotment was originally made pursuant to shareholder approval obtained in the Extra-Ordinary General Meeting held on October 22, 2025.

Fredun Pharmaceuticals Limited conducted analyst and institutional investor meetings on March 25, 2026, in compliance with SEBI listing regulations. The pharmaceutical company engaged with a diverse group of investment professionals and high net worth individuals through a structured virtual meeting format.

Meeting Structure and Participation

The company organized a single comprehensive session lasting 40 minutes, from 12:00 PM to 12:40 PM, conducted via Zoom. A total of 38 participants joined the meeting, representing a broad spectrum of the investment community.

Institutional Participation

The meeting attracted representatives from 24 prominent investment organizations, demonstrating significant institutional interest in the company. Key participating firms included:

• Asset Management Companies: Cognizant Capital, A.J. Capital, Allbridge Capital, Dhyana Capital, Helios Capital
• Investment Firms: Tiger Assets, Fyers Assets, PI Square Investments, BlueOcean Asset Management, Alpha AMC
• Research and Advisory: 9 Rays EquiReseach, Lorvet Consultancy, Blue Banyan Advisors
• Venture Capital: Samdareeya Capital Ventures, Ninedot Ventures, Greengen Capital Partners
• Other Financial Services: SmartSync Services, Navrathan & Co., BK Securities

High Net Worth Individual Engagement

The meeting also included 14 high net worth individuals (HNIs), reflecting retail investor interest in the pharmaceutical company. This diverse participation base indicates broad market attention across both institutional and individual investor segments.

Meeting Outcomes and Compliance

The management team provided participants with comprehensive insights into the company's operations while maintaining strict regulatory compliance. Key discussion areas included:

• Business Operations Overview: Management shared details about current business activities and operational performance
• Industry Outlook: Discussions covered the pharmaceutical sector's prospects and market dynamics
• Growth Strategy: The company outlined its strategic initiatives and expansion plans

Importantly, the company ensured all discussions remained within the bounds of publicly available information, with no unpublished price sensitive information (UPSI) shared during the session.

Regulatory Compliance

This disclosure was made pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company had previously intimated about these meetings on March 21, 2026, demonstrating proactive compliance with regulatory requirements. The structured approach to investor engagement reflects the company's commitment to transparency and regulatory adherence in its stakeholder communications.